Rock Springs Capital Management’s Krystal Biotech KRYS Stock Holding History

Rock Springs Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-55,861	Closed	-$10.2M	–	116
2024 Q3	$10.2M	Sell	55,861 -49,708	-47%	-$9.58M	0.33%	69
2024 Q2	$19.4M	Buy	105,569 +1,600	+2%	+$269K	0.58%	53
2024 Q1	$18.5M	Hold	103,969	–	–	0.47%	61
2023 Q4	$12.9M	Buy	103,969 +13,409	+15%	+$1.49M	0.32%	67
2023 Q3	$10.5M	Buy	90,560 +55,659	+159%	+$6.79M	0.28%	72
2023 Q2	$4.1M	Buy	+34,901	New	+$3.56M	0.1%	90

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rock Springs Capital Management's KRYS Position: Q4 2024 in Review

Rock Springs Capital Management sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 55,861 shares — an estimated $10.2M sold.

Rock Springs Capital Management first reported a position in KRYS in Q2 2023 and held it in 6 quarters. The position peaked at $19.4M in Q2 2024. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

Rock Springs Capital Management reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
Rock Springs Capital Management sold 55,861 Krystal Biotech shares in Q4 2024, an estimated $10.2M.
Rock Springs Capital Management first reported a position in Krystal Biotech in Q2 2023 and held it in 6 quarters.
Rock Springs Capital Management's Krystal Biotech position peaked at $19.4M in Q2 2024.
264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on Rock Springs Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.